Fig. 1.
TβRIII inhibits cell migration in epithelial and cancer cells. (A) Cancer cell lines stably expressing TβRIII with Neo as controls (Ovca429 and MDA-MB231) and transiently expressing TβRIII with GFP as control (Ovca433 and Ovca3) were allowed to migrate for 18–24 h toward 10% FBS (see Materials and Methods). Fold migration relative to controls is presented and data represent the mean ± SE of 3 independent experiments performed in triplicate. The number of cells migrated is presented in Fig. S1A. (B) Ovca429 cells transiently expressing either TβRIII, TβRIIIΔGAG, TβRIIIΔCYTO, or GFP were allowed to migrate for 18–24 h toward 10% FBS. Data represent the mean ± SE of 3 independent experiments performed in triplicate. The number of cells migrated is presented in Fig. S1B. (C) NOSE007 cells in SFM in the top chamber of a transwell were allowed to migrate for 18–24 h toward 10% FBS 72 h after infection with adenovirus-expressing shRNA NTCs, human shRNA-TβRIII alone, human shRNA-TβRIII after infection with rat TβRIII (rTβRIII), or 48 h after infection with TβRIII, TβRIIIΔGAG, TβRIIIΔCYTO and GFP as controls. Fold migration relative to controls (shRNA NTCs for shRNA-TβRIII-infected cells or GFP control) is presented. Data represent the mean ± SE of 3 independent experiments performed in duplicate. *, P = 0.0036, relative to control. The number of cells migrated is presented in Fig. S1 C and D.